

RESEARCH

Mphasis | Target: Rs 1,410 | +4% | REDUCE

DXC remains soft but pipeline healthy – raise to REDUCE

BOB Economics Research | October MPC Minutes

Emphasis on forward guidance

Tech Mahindra | Target: Rs 980 | +16% | BUY

Communication vertical recovers; TCV robust

JK Tyre & Industries | Target: Rs 85 | +17% | BUY

Strong Q2FY21; focus on debt reduction continues

SUMMARY

Mphasis

Mphasis (MPHL) reported strong Q2FY21 revenue and margins. Revenue grew 6% QoQ CC despite DXC business dropping 14.9%. EBIT margin at 16.1% improved 40bps QoQ (15.7% est.). TCV at US\$ 360mn was at its peak on the back of a healthy order book. We increase FY21-FY23 EPS by 5-10% and roll over to a revised Sep'21 TP of Rs 1,410 (vs. Rs 950). Though risks to the DXC business persist, we reset our target P/E to 16.4x based on MPHL's strong pipeline and diverse revenue mix. Raise to REDUCE from SELL.

[Click here for the full report.](#)

India Economics: October MPC Minutes

MPC members favoured forward guidance on accommodative conditions to anchor market expectations of liquidity. This along with purchase of government securities has led to reduction in term premium. Minutes show MPC members believe inflation will ease as supply restrictions are removed. Demand conditions are weak. So is pricing power with corporates. On growth, members believe consumption recovery may be short lived and an investment led recovery is likely to take time and contingent on public sector spending.

[Click here for the full report.](#)

TOP PICKS

LARGE-CAP IDEAS

| Company | Rating | Target |
|-------------------------------|--------|--------|
| Bajaj Finance | Buy | 4,000 |
| Cipla | Buy | 850 |
| GAIL | Buy | 155 |
| Petronet LNG | Buy | 310 |
| Tech Mahindra | Buy | 980 |

MID-CAP IDEAS

| Company | Rating | Target |
|----------------------------------|--------|--------|
| Alkem Labs | Buy | 3,600 |
| Chola Investment | Buy | 280 |
| Laurus Labs | Buy | 1,200 |
| Transport Corp | Buy | 270 |
| Mahanagar Gas | Sell | 750 |

Source: BOBCAPS Research

DAILY MACRO INDICATORS

| Indicator | Current | 2D (%) | 1M (%) | 12M (%) |
|------------------------|---------|------------------|-----------|----------|
| US 10Y yield (%) | 0.86 | 3bps | 19bps | (91bps) |
| India 10Y yield (%) | 5.91 | 0bps | (10bps) | (59bps) |
| USD/INR | 73.54 | 0.1 | (0.2) | (3.5) |
| Brent Crude (US\$/bbl) | 42.46 | 1.7 | 2.5 | (31.1) |
| Dow | 28,364 | 0.5 | 4.5 | 5.8 |
| Shanghai | 3,313 | (0.4) | (0.1) | 12.6 |
| Sensex | 40,558 | (0.4) | 6.6 | 3.9 |
| India FII (US\$ mn) | 21 Oct | MTD | CYTD | FYTD |
| FII-D | (18.2) | 297.8 (14,382.0) | (4,622.5) | |
| FII-E | 287.9 | 2,001.0 | 6,041.1 | 12,644.1 |

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



Tech Mahindra

Tech Mahindra (TECHM) posted 2.9% QoQ CC revenue growth and stellar 390bps EBITDA margin expansion, bettering our estimates for Q2FY21. The telecom vertical has finally started recovering (+3% QoQ USD). Traction in the TME, BFSI and retail segments led QoQ recovery for the enterprise segment. TCV was robust at US\$ 421mn. We raise FY21-FY23 EPS by 7-10% to bake in the Q2 beat and roll over to a revised Sep'21 TP of Rs 980 (Rs 910 earlier), based on an unchanged target P/E of 15.7x. Reiterate BUY.

[Click here for the full report.](#)

JK Tyre & Industries

JK Tyre (JKI) surprised positively on both revenue and earnings in Q2FY21, led by strong replacement demand and above-expected operating efficiencies. Revenue was up 6% YoY to Rs 22.7bn while operating margins expanded 180bps YoY. Through efficient working capital management, JKI also reduced debt by Rs 6bn in H1FY21. With no major capex lined up in the near term, we expect better leverage ratios going ahead. Maintain BUY with an unchanged Sep'21 TP of Rs 85, set at 7x Sep'22E EPS.

[Click here for the full report.](#)

REDUCE

TP: Rs 1,410 | ▲ 4%

MPHASIS

| IT Services

| 23 October 2020

DXC remains soft but pipeline healthy – raise to REDUCE

Mphasis (MPHL) reported strong Q2FY21 revenue and margins. Revenue grew 6% QoQ CC despite DXC business dropping 14.9%. EBIT margin at 16.1% improved 40bps QoQ (15.7% est.). TCV at US\$ 360mn was at its peak on the back of a healthy order book. We increase FY21-FY23 EPS by 5-10% and roll over to a revised Sep'21 TP of Rs 1,410 (vs. Rs 950). Though risks to the DXC business persist, we reset our target P/E to 16.4x based on MPHL's strong pipeline and diverse revenue mix. Raise to REDUCE from SELL.

Ruchi Burde | Seema Nayak

research@bobcaps.in

Diversified revenue mix: Revenue growth of 6% QoQ CC beat our estimate of 1.6% due to a strong pickup in direct revenue (10.9% QoQ CC), which offset a 14.9% revenue decline in DXC. Strong momentum in banking and capital markets aided revenue mix diversification. Overall, QoQ growth was uplifted by higher investment in sales, improved client mining and a focus on Europe revenues as well as direct channel growth. EBIT margin stood at 16.1%, expanding 40bps QoQ, marginally outperforming our estimate of 15.7%.

TCV at record high: Direct business TCV stood at an all-time high of US\$ 360mn in Q2, coming from the areas of cloud, modernisation and big data. About 73% of TCV was from new-gen areas. MPHL's cloud pipeline has grown 3x YoY. TTM deal wins crossed US\$ 1bn for the first time in Q2. MPHL saw increased number of large deals bagged (US\$ 200mn+ TCV), with most of them being transformation-led and integrated in nature.

Improved growth visibility: MPHL's outlook on the banking and capital markets vertical remains upbeat. Europe is expected to remain a significant growth driver even beyond FY21. Per management, the pipeline is up 75% YoY, lending improved visibility for the near-to-mid-term. EBIT margin is guided to lie within 15.5-16.5% in FY21.

| | |
|------------------|------------------|
| Ticker/Price | MPHL IN/Rs 1,350 |
| Market cap | US\$ 3.4bn |
| Shares o/s | 186mn |
| 3M ADV | US\$ 9.6mn |
| 52wk high/low | Rs 1,465/Rs 630 |
| Promoter/FPI/DII | 52%/29%/14% |

Source: NSE

STOCK PERFORMANCE

Source: NSE

KEY FINANCIALS

| Y/E 31 Mar | FY19A | FY20A | FY21E | FY22E | FY23E |
|-------------------------|--------|--------|--------|---------|---------|
| Total revenue (Rs mn) | 77,311 | 88,436 | 98,575 | 115,343 | 129,106 |
| EBITDA (Rs mn) | 13,240 | 16,505 | 18,228 | 22,667 | 25,408 |
| Adj. net profit (Rs mn) | 10,734 | 11,849 | 12,141 | 15,160 | 17,092 |
| Adj. EPS (Rs) | 57.7 | 63.7 | 65.2 | 81.4 | 91.8 |
| Adj. EPS growth (%) | 30.9 | 10.4 | 2.5 | 24.9 | 12.7 |
| Adj. ROAE (%) | 20.0 | 21.4 | 19.9 | 22.5 | 22.9 |
| Adj. P/E (x) | 23.4 | 21.2 | 20.7 | 16.6 | 14.7 |
| EV/EBITDA (x) | 18.8 | 15.2 | 13.8 | 11.1 | 9.7 |

Source: Company, BOBCAPS Research



OCTOBER MPC MINUTES

23 October 2020

Emphasis on forward guidance

MPC members favoured forward guidance on accommodative conditions to anchor market expectations of liquidity. This along with purchase of government securities has led to reduction in term premium. Minutes show MPC members believe inflation will ease as supply restrictions are removed. Demand conditions are weak. So is pricing power with corporates. On growth, members believe consumption recovery may be short lived and an investment led recovery is likely to take time and contingent on public sector spending.

Sameer Narang

Jahnvi | Sonal Badhan

chief.economist@bankofbaroda.com

Growth to recover gradually: MPC stated that growth is expected to recover gradually from a steep contraction in Q1, as several economic indicators suggest a pickup in activity. A second wave of COVID-19 infections pose a risk to growth. MPC members also pointed out that potential output may take several years to repair. Dr. Patra noted that empirical evidence suggests that consumption led recoveries are shallow and short-lived. In addition, he believes there is an anecdotal sense that economy's potential output has fallen.

Inflationary pressures to subside: All the MPC members were of the view that inflation will begin to subside from Q3FY21 onwards with Dr. Saggiar expecting a decline beginning in Oct'20 with headline converging to core inflation, and both softening. The key reasons for this are: removal of supply side bottlenecks, good monsoon and weak demand. According to Dr. Patra, deviation of inflation from its target was mainly owing to supply shocks in food and fuel category (71% contribution), followed by unanchored inflation expectations (28%) and exchange rate and asset prices (12%). Inflation is pulled down by 15% by negative demand shock.

MPC remains accommodative: Shri Shaktikanta Das, RBI Governor, noted that there exists space for rate cuts if inflation evolves in line with expectations. In the current policy, focus was on forward guidance. Shri Das stated that enhanced guidance should strengthen and quicken the pace of transmission to longer-term yields. Dr. Patra too said that policy should remain accommodative and exploit the headroom that opens up when inflation recedes. With supply side restrictions easing, RBI expects inflation to recede to 5.4% in Q3 and 4.5% in Q4. It will settle in the range of 4.1-4.4% next year. Any further increase in international commodity prices and mean reversion in certain core inflation categories may lead to an upward surprise.

KEY HIGHLIGHTS

- MPC members see inflation ebbing in H2FY21.
- Growth to recover only gradually.
- Further rate cuts seem difficult.



BUY

TP: Rs 980 | ▲ 16%

TECH MAHINDRA

| IT Services

| 23 October 2020

Communication vertical recovers; TCV robust

Tech Mahindra (TECHM) posted 2.9% QoQ CC revenue growth and stellar 390bps EBITDA margin expansion, bettering our estimates for Q2FY21. The telecom vertical has finally started recovering (+3% QoQ USD). Traction in the TME, BFSI and retail segments led QoQ recovery for the enterprise segment. TCV was robust at US\$ 421mn. We raise FY21-FY23 EPS by 7-10% to bake in the Q2 beat and roll over to a revised Sep'21 TP of Rs 980 (Rs 910 earlier), based on an unchanged target P/E of 15.7x. Reiterate BUY.

Ruchi Burde | Seema Nayak

research@bobcaps.in

Strong growth momentum: Revenue growth of 2.9% QoQ CC exceeded our estimate of 1.3%, backed equally by growth in supply and demand. The enterprise segment grew 4.3% QoQ CC and communication was up 0.8% after two quarters of decline. Within enterprise, technology, media and entertainment (TME), BFSI and retail revived the most. Alliances with cloud hyperscalers have also seen increased focus. EBIT margin at 14.2% surged 410bps QoQ on lower SG&A and employee cost. Margin tailwinds arose from the supply and demand side (+160bps each), increased cost efficiency (+160bps); offset by normalisation from seasonality (-70bps).

Deal win recovery: With numerous multiyear wins across the software engineering services, communication, healthcare, ENU and BFSI verticals, net new TCV stood at US\$ 421mn (+45% QoQ, -72% YoY). Q2 TCV was a mix of large- and medium-sized deals. Communication segment wins totaled US\$ 208mn and enterprise US\$ 214mn. The deal funnel is also at an all-time high.

Positive outlook: The communication vertical recovered as a few deal reversals from Q1 were recouped. The 5G space is expected to see increased activity in coming quarters, especially in services and core digital transformation. TECHM expects retail and manufacturing to recover from Q3.

| | |
|------------------|-----------------|
| Ticker/Price | TECHM IN/Rs 848 |
| Market cap | US\$ 10.1bn |
| Shares o/s | 873mn |
| 3M ADV | US\$ 63.0mn |
| 52wk high/low | Rs 888/Rs 471 |
| Promoter/FPI/DII | 36%/39%/25% |

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

| Y/E 31 Mar | FY19A | FY20A | FY21E | FY22E | FY23E |
|-------------------------|---------|---------|---------|---------|---------|
| Total revenue (Rs mn) | 347,421 | 368,677 | 385,822 | 448,388 | 501,377 |
| EBITDA (Rs mn) | 63,368 | 57,261 | 66,649 | 81,088 | 90,275 |
| Adj. net profit (Rs mn) | 42,975 | 42,505 | 45,483 | 51,911 | 57,976 |
| Adj. EPS (Rs) | 47.7 | 48.3 | 51.7 | 59.0 | 65.9 |
| Adj. EPS growth (%) | 11.9 | 1.2 | 7.0 | 14.1 | 11.7 |
| Adj. ROAE (%) | 21.4 | 19.8 | 19.4 | 19.8 | 19.9 |
| Adj. P/E (x) | 17.8 | 17.6 | 16.4 | 14.4 | 12.9 |
| EV/EBITDA (x) | 11.6 | 12.9 | 11.0 | 8.9 | 7.6 |

Source: Company, BOBCAPS Research



BUY

TP: Rs 85 | ▲ 17%

JK TYRE & INDUSTRIES

Auto Components

23 October 2020

Strong Q2FY21; focus on debt reduction continues

JK Tyre (JKI) surprised positively on both revenue and earnings in Q2FY21, led by strong replacement demand and above-expected operating efficiencies. Revenue was up 6% YoY to Rs 22.7bn while operating margins expanded 180bps YoY. Through efficient working capital management, JKI also reduced debt by Rs 6bn in H1FY21. With no major capex lined up in the near term, we expect better leverage ratios going ahead. Maintain BUY with an unchanged Sep'21 TP of Rs 85, set at 7x Sep'22E EPS.

Mayur Milak | Nishant Chowhan, CFA
research@bobcaps.in

Strong Q2FY21: At Rs 22.7bn (+6% YoY), consolidated revenue was 10% ahead of our estimate, led by strong traction in the farm and MHCV segments. Replacement volumes grew 22% YoY, ahead of overall volume growth of ~12%. Softer raw material costs and better operating efficiencies further boosted EBITDA margins to 15.6%, up 180bps YoY. Adj. PAT for Q2 declined 59% YoY to Rs 890mn due to a one-off tax reversal gain in Q2FY20.

| | |
|------------------|--------------|
| Ticker/Price | JKI IN/Rs 73 |
| Market cap | US\$ 243.4mn |
| Shares o/s | 246mn |
| 3M ADV | US\$ 1.1mn |
| 52wk high/low | Rs 88/Rs 32 |
| Promoter/FPI/DII | 56%/3%/1% |

Source: NSE

Potential rerating in sight: Despite negative earnings growth in FY20, JKI managed to reduce its net D/E to 2.1x (from 2.4x in FY19). Further, led by efficient working capital management, the company also reduced its debt by Rs 6bn in H1FY21 (overall debt reduction of Rs 12bn in the last one year). While we currently value the stock at 7x one-year forward EPS, a discount of 60% to the market leader, we see a case for rerating as leverage ratios improve.

STOCK PERFORMANCE



Source: NSE

Maintain BUY: We forecast a revenue/EBITDA/PAT CAGR of 9%/11%/13% for JKI over FY20-FY23, backed by strong replacement demand, reviving offtake from OEMs and benign raw material prices. Maintain BUY with a Sep'21 TP of Rs 85.

KEY FINANCIALS

| Y/E 31 Mar | FY19A | FY20A | FY21E | FY22E | FY23E |
|-------------------------|---------|--------|--------|---------|---------|
| Total revenue (Rs mn) | 103,699 | 87,249 | 83,648 | 101,189 | 111,931 |
| EBITDA (Rs mn) | 10,251 | 9,876 | 9,774 | 12,092 | 13,441 |
| Adj. net profit (Rs mn) | 1,706 | 2,472 | 887 | 2,595 | 3,561 |
| Adj. EPS (Rs) | 6.9 | 10.0 | 3.6 | 10.5 | 14.5 |
| Adj. EPS growth (%) | 137.9 | 44.9 | (64.1) | 192.5 | 37.2 |
| Adj. ROAE (%) | 7.0 | 10.2 | 3.5 | 9.5 | 11.7 |
| Adj. P/E (x) | 10.5 | 7.3 | 20.2 | 6.9 | 5.0 |
| EV/EBITDA (x) | 7.1 | 7.5 | 7.2 | 5.5 | 4.8 |

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 30 September 2020, out of 104 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 54 have BUY ratings, 18 have ADD ratings, 10 are rated REDUCE and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.